FibroGen’s (FGEN) “Buy” Rating Reaffirmed at HC Wainwright

FibroGen (NASDAQ:FGEN)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $10.00 target price on the biopharmaceutical company’s stock.

Separately, StockNews.com initiated coverage on FibroGen in a research note on Friday. They issued a “hold” rating on the stock.

FibroGen Stock Performance

Shares of FibroGen stock traded down $0.07 during midday trading on Tuesday, hitting $0.38. The company had a trading volume of 1,744,862 shares, compared to its average volume of 2,318,862. The stock has a market capitalization of $37.79 million, a P/E ratio of -0.30 and a beta of 0.82. The company has a 50 day moving average of $0.51 and a 200 day moving average of $0.43. FibroGen has a 52-week low of $0.18 and a 52-week high of $2.80.

Institutional Trading of FibroGen

Several institutional investors have recently added to or reduced their stakes in the business. Mackenzie Financial Corp boosted its stake in FibroGen by 416.6% during the 4th quarter. Mackenzie Financial Corp now owns 546,959 shares of the biopharmaceutical company’s stock valued at $290,000 after purchasing an additional 441,083 shares during the last quarter. Velan Capital Investment Management LP purchased a new stake in FibroGen during the 4th quarter valued at $42,000. Squarepoint Ops LLC purchased a new stake in FibroGen during the 4th quarter valued at $205,000. Two Sigma Investments LP boosted its stake in shares of FibroGen by 19.6% in the 4th quarter. Two Sigma Investments LP now owns 604,421 shares of the biopharmaceutical company’s stock worth $320,000 after buying an additional 98,888 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its stake in shares of FibroGen by 18.3% in the 4th quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock worth $465,000 after buying an additional 135,600 shares during the last quarter. 72.71% of the stock is currently owned by hedge funds and other institutional investors.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.